Detection of Early Esophageal Cancer by Near-Infrared Fluorescence molecular Endoscopy using Bevacizumab-800CW - Fluorescence endoscopy of early stages of esophageal cancer.

niversity Medical Center Groningen0 个研究点目标入组 60 人开始时间: 2019年1月31日最近更新: 2021年1月5日

适应症

试验速览

暂无简介。

•Suspicion or diagnosed LGD, HGD or superficial EAC and planned diagnostic and/or therapeutic endoscopy.
•Mentally competent person, 18 years or older.
•dequate potential for 5-year follow-up.
•Written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•Patients younger than 18 years old
•Submucosal and invasive EAC; EAC with TNM-classification other than T1.
•Radiation therapy for esophageal cancer
•Immunoglobulin allergy
•Chemotherapy, immunotherapy or surgery 28 days before administration of the tracer
•Prior Bevacizumab treatment
•Non-adjustable hypertension
•Medical or psychiatric conditions that compromise the patient’s ability to give informed consent.
•Pregnancy or breast feeding.

发起方